Travere Therapeutics, Inc. TVTX Total net product sales — Total Revenue

Other product segments

Similar metrics at other companies

NBIXNet product sales — Total revenues

$811M+43.9%

BMYNet product sales — Total Revenues

$11.17B+2.6%

MIRMProduct sales, net — Product sales, net

$159.88M+43.3%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

BIIBProduct revenue, net — Total Revenue

$1.75B+1.5%

MRNANet product sales — Total Revenue

$352M+309%

Questions, answered.

What is Travere Therapeutics, Inc.'s total net product sales — total revenue?

Travere Therapeutics, Inc. (TVTX) reported total net product sales — total revenue of $124.49M in Q1 2026.

How has Travere Therapeutics, Inc.'s total net product sales — total revenue changed year-over-year?

Travere Therapeutics, Inc.'s total net product sales — total revenue increased by 64.1% year-over-year, from $75.86M to $124.49M.

What is the long-term trend for Travere Therapeutics, Inc.'s total net product sales — total revenue?

Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s total net product sales — total revenue has grown at a 40.3% compound annual growth rate (CAGR), from $148.58M to $410.46M.

What does total net product sales — total revenue mean?

This metric represents the total revenue generated from the sale of pharmaceutical products after accounting for returns, rebates, and other sales deductions. It serves as a primary indicator of the commercial adoption and market penetration of the company's therapeutic portfolio. Tracking this figure allows investors to assess the growth trajectory and revenue-generating capacity of the company's core product offerings.